Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
149.40
+3.53 (2.42%)
Aug 10, 2026, 10:42 AM EDT - Market open

Protagonist Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
281.9946.02434.436026.5827.36
Revenue Growth
34.81%-89.41%624.05%125.72%-2.84%-4.44%
Gross Profit
281.9946.02434.436026.5827.36
Selling, General & Admin
48.4944.8543.4633.4931.7427.2
Research & Development
175.16159.29138.13120.16126.22126.01
Total Operating Expenses
223.65204.14181.59153.65157.95153.2
Operating Income
58.34-158.13252.84-93.65-131.37-125.85
Interest Income
26.1228.7926.3214.94.060.44
Other Non-Operating Income (Expense)
-0.120.030.25-0.2-0.08-0.15
Total Non-Operating Income (Expense)
2628.8226.5714.73.980.29
Pretax Income
84.34-129.31279.41-78.96-127.39-125.55
Provision for Income Taxes
4.780.844.22---
Net Income
-39.34-130.15275.19-78.96-127.39-125.55
Net Income to Common
-39.34-130.15275.19-78.96-127.39-125.55
Net Income Growth
------
Shares Outstanding (Basic)
656462574946
Shares Outstanding (Diluted)
676465574946
Shares Change
5.75%-2.31%14.65%15.74%5.87%34.67%
EPS (Basic)
1.22-2.054.47-1.39-2.60-2.71
EPS (Diluted)
1.03-2.054.23-1.39-2.60-2.71
EPS Growth
47.14%-----
Free Cash Flow
130.5856.08182.8-70.85-108.93-108.97
Free Cash Flow Growth
251.98%-69.32%----
Free Cash Flow Per Share
1.940.882.81-1.25-2.22-2.35
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
20.69%-343.63%58.20%-156.09%-494.24%-460.01%
Profit Margin
-13.95%-282.83%63.34%-131.59%-479.26%-458.94%
FCF Margin
46.31%121.87%42.08%-118.08%-409.81%-398.31%
EBITDA
59.88-156.85253.67-92.68-130.34-125.03
EBITDA Margin
21.24%-340.85%58.39%-154.46%-490.35%-457.04%
EBIT
58.34-158.13252.84-93.65-131.37-125.85
EBIT Margin
20.69%-343.63%58.20%-156.09%-494.24%-460.01%
Effective Tax Rate
5.66%-0.65%1.51%0.00%0.00%0.00%
SEC Filings: 10-K · 10-Q